Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongyi Liang

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Clinical & Experimental Metastasis|April 11, 2025
Ras-proximate-1 (RAP1): a prognosis and therapeutic target in the metastatic spread of breast cancerHongyi Liang, Guoliang Yin, Dandan Feng, et al.
Frontiers in Pharmacology|December 12, 2022
Shuangyu Tiaozhi decoction alleviates non-alcoholic fatty liver disease by improving lipid deposition, insulin resistance, and inflammation <i>in vitro</i> and <i>in vivo</i>Guoliang Yin, Hongyi Liang, Wenxiu Sun, et al.
Chemico-Biological Interactions|November 13, 2024
Diosgenin attenuates nonalcoholic fatty liver disease through mTOR-mediated inhibition of lipid accumulation and inflammationGuoliang Yin, Hongyi Liang, Yiran Cheng, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|December 4, 2024
[Real-world Study of the Safety and Efficacy of Pembrolizumab in the Treatment 
of Advanced Non-small Cell Lung Cancer]Ning Wan, Bing Wang, Ya Guo, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Clinical & Experimental Metastasis|April 11, 2025
Ras-proximate-1 (RAP1): a prognosis and therapeutic target in the metastatic spread of breast cancerHongyi Liang, Guoliang Yin, Dandan Feng, et al.
Frontiers in Pharmacology|December 12, 2022
Shuangyu Tiaozhi decoction alleviates non-alcoholic fatty liver disease by improving lipid deposition, insulin resistance, and inflammation <i>in vitro</i> and <i>in vivo</i>Guoliang Yin, Hongyi Liang, Wenxiu Sun, et al.
Chemico-Biological Interactions|November 13, 2024
Diosgenin attenuates nonalcoholic fatty liver disease through mTOR-mediated inhibition of lipid accumulation and inflammationGuoliang Yin, Hongyi Liang, Yiran Cheng, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|December 4, 2024
[Real-world Study of the Safety and Efficacy of Pembrolizumab in the Treatment 
of Advanced Non-small Cell Lung Cancer]Ning Wan, Bing Wang, Ya Guo, et al.
Pageof 2